Financhill
Sell
19

EVO Quote, Financials, Valuation and Earnings

Last price:
$3.8000
Seasonality move :
2.52%
Day range:
$3.7600 - $3.8900
52-week range:
$2.8400 - $5.6405
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.58x
P/B ratio:
1.35x
Volume:
166K
Avg. volume:
157.8K
1-year change:
-16.63%
Market cap:
$1.3B
Revenue:
$862.6M
EPS (TTM):
-$0.63

Analysts' Opinion

  • Consensus Rating
    Evotec SE has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $6.0115, Evotec SE has an estimated upside of 59.88% from its current price of $3.7600.
  • Price Target Downside
    According to analysts, the lowest downside price target is $3.0781 representing 100% downside risk from its current price of $3.7600.

Fair Value

  • According to the consensus of 2 analysts, Evotec SE has 59.88% upside to fair value with a price target of $6.0115 per share.

EVO vs. S&P 500

  • Over the past 5 trading days, Evotec SE has underperformed the S&P 500 by -15.19% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Evotec SE does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Evotec SE revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Evotec SE reported revenues of $210.4M.

Earnings Growth

  • Evotec SE has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Evotec SE reported earnings per share of -$0.09.
Enterprise value:
991.2M
EV / Invested capital:
0.94x
Price / LTM sales:
1.58x
EV / EBIT:
--
EV / Revenue:
1.17x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-12.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$114.8M
Return On Assets:
-10.26%
Net Income Margin (TTM):
-26.32%
Return On Equity:
-20.84%
Return On Invested Capital:
-14.69%
Operating Margin:
-9.91%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $834.1M $842.9M $845.7M $226.7M $210.4M
Gross Profit $203M $170M $114.8M $37.8M $28.6M
Operating Income $34.3M -$62.5M -$87.1M -$19.8M -$20.9M
EBITDA -$82.2M -$96.9M -$200.1M -$26.2M -$28.9M
Diluted EPS -$0.34 -$0.28 -$0.63 -$0.07 -$0.09
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $797.6M $1.2B -- $892.2M $783.5M
Total Assets $1.9B $2.4B -- $2.4B $2.1B
Current Liabilities $280.9M $379.1M -- $478.4M $386.3M
Total Liabilities $923.4M $976.8M -- $1.2B $1.1B
Total Equity $929.7M $1.5B -- $1.2B $987.2M
Total Debt $431.9M $404.3M -- $677.7M $65.9M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $146.3M -$13.6M $38.6M -$52.3M -$33.5M
Cash From Investing -$332.9M -$43M -$66.2M -$33.6M -$22.7M
Cash From Financing -$59.1M $75.3M -$131.1M -$6.4M $37.3M
Free Cash Flow -$43.1M -$248.1M -$80.6M -$99.3M -$56.4M
EVO
Sector
Market Cap
$1.3B
$32.8M
Price % of 52-Week High
66.66%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-16.63%
-35.38%
Beta (5-Year)
1.656
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $4.1225
200-day SMA
Sell
Level $4.0064
Bollinger Bands (100)
Sell
Level 3.5163 - 4.3963
Chaikin Money Flow
Sell
Level -63.5M
20-day SMA
Sell
Level $4.1008
Relative Strength Index (RSI14)
Sell
Level 41.3744
ADX Line
Sell
Level 9.4381
Williams %R
Buy
Level -100
50-day SMA
Sell
Level $3.9901
MACD (12, 26)
Sell
Level -0.0015
25-day Aroon Oscillator
Sell
Level -72
On Balance Volume
Neutral
Level 25M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.7131)
Sell
CA Score (Annual)
Level (-0.7226)
Buy
Beneish M-Score (Annual)
Level (-2.6044)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (0.2906)
Buy
Piotroski F Score (Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Stock Forecast FAQ

In the current month, EVO has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The EVO average analyst price target in the past 3 months is $6.0115.

  • Where Will Evotec SE Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Evotec SE share price will rise to $6.0115 per share over the next 12 months.

  • What Do Analysts Say About Evotec SE?

    Analysts are divided on their view about Evotec SE share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evotec SE is a Sell and believe this share price will drop from its current level to $3.0781.

  • What Is Evotec SE's Price Target?

    The price target for Evotec SE over the next 1-year time period is forecast to be $6.0115 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is EVO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Evotec SE is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.

  • How Can I Buy Shares Of EVO?

    You can purchase shares of Evotec SE via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evotec SE shares.

  • What Is The Evotec SE Share Price Today?

    Evotec SE was last trading at $3.8000 per share. This represents the most recent stock quote for Evotec SE. Yesterday, Evotec SE closed at $3.7600 per share.

  • How To Buy Evotec SE Stock Online?

    In order to purchase Evotec SE stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Warren Buffett Buy Amazon Stock?
Why Did Warren Buffett Buy Amazon Stock?

When investors think of tech stocks in Warren Buffett’s portfolio,…

Where Will RocketLab Stock Be In 5 Years?
Where Will RocketLab Stock Be In 5 Years?

Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…

Is MO dividend Worth It?
Is MO dividend Worth It?

Altria Group (NYSE: MO) is paying investors $1.02 a share…

Stock Ideas

Buy
64
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
83
GMS alert for Jun 23

GMS [GMS] is up 0.03% over the past day.

Buy
54
SMLR alert for Jun 23

Semler Scientific [SMLR] is up 16.13% over the past day.

Buy
57
GXO alert for Jun 23

GXO Logistics [GXO] is up 2.42% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock